Cellyan Biotechnology Co., LtdHKPD

Hong Kong Pharma Digital Tech Co., Ltd-trading under the ticker 1187 on the Stock Exchange of Hong Kong-is a digital health company whose public identity begins and ends with a product page and a trio of press releases, two of which date from 2020 and one from 2022. The company’s core claim is to operate a ‘smart pharmacy platform’ that digitises prescriptions, pill vending, and patient queues across Asia, but the evidence it offers is a single static image of a pill box beside a QR code on a phone screen and a locked office door in Kowloon. There is no public filing, no audited accounts, no revenue line, no customer roster, and no live demonstration on its website. What is visible is a polished deck that promises infrastructure without any infrastructure to show.

The platform story rests on two rails: a product page titled ‘Our Service’ and a press archive titled ‘Press Releases.’ The product page describes a ‘smart pharmacy kiosk’ and a ‘digital prescription wallet,’ but neither the kiosk nor the wallet appears with a customer, a contract, or a deployed unit. The press releases are similarly sparse: one announces a ‘launch’ of the kiosk in 2020, another touts a ‘digital prescription wallet’ in 2022, and the third is a placeholder with no material detail. The company’s public footprint is therefore a slide, a locked door, and a single product image-an aesthetic that matches the ambition far better than the execution.

The company has not filed any audited financial statements, quarterly results, or segmental breakdowns on its website or via the HKEX portal, which means no revenue, no net income, no EPS, no operating cash flow, and no capital ratios are available from the issuer’s own rails. The only concrete asset is the product image of a striped pill box beside a phone screen displaying a QR code, which proves at least that someone drew a pill box and a QR code, not that anyone is selling, servicing, or counting them. The absence of filings is the presence of opacity: the platform story is built on air, and the only solid ground is the image of the pill box itself.

There is The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. The only market mechanism that is visible is the company’s own website, which is the sole source of its product claims and press archive; beyond that, there is no liquidity depth, no venue data, and no exchange plumbing to assess. As of today, the market for 1187 is not a trading screen; it is a locked door with an unanswered intercom.

The tension is structural: the company’s narrative promises a digital health platform that streamlines prescriptions and queues across Asia, but the evidence it supplies is a product page, a pair of ancient press releases, and a candy-striped pill box image. Until the company files audited accounts, discloses revenue, or shows a single live deployment with a customer contract, the platform story remains a slide deck and the stock remains an unopened drawer. What would change the file is a filing that proves revenue, customers, or cash-any one of which would at least ground the platform story in something more substantial than a QR code on a slide.